CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Profitability
This table compares CASI Pharmaceuticals and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CASI Pharmaceuticals | -183.93% | N/A | -131.54% |
| Pyxis Oncology | N/A | -135.60% | -85.00% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for CASI Pharmaceuticals and Pyxis Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CASI Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
| Pyxis Oncology | 1 | 1 | 7 | 0 | 2.67 |
Valuation and Earnings
This table compares CASI Pharmaceuticals and Pyxis Oncology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CASI Pharmaceuticals | $26.85 million | 0.10 | -$39.26 million | ($3.01) | -0.07 |
| Pyxis Oncology | $13.86 million | 10.79 | -$79.62 million | ($1.31) | -1.80 |
CASI Pharmaceuticals has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Institutional and Insider Ownership
22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Pyxis Oncology beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
About Pyxis Oncology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
